Literature DB >> 16584126

Symbiotic relationship of pharmacogenetics and drugs of abuse.

Joni L Rutter1.   

Abstract

Pharmacogenetics/pharmacogenomics is the study of how genetic variation affects pharmacology, the use of drugs to treat disease. When drug responses are predicted in advance, it is easier to tailor medications to different diseases and individuals. Pharmacogenetics provides the tools required to identify genetic predictors of probable drug response, drug efficacy, and drug-induced adverse events-identifications that would ideally precede treatment decisions. Drug abuse and addiction genetic data have advanced the field of pharmacogenetics in general. Although major findings have emerged, pharmacotherapy remains hindered by issues such as adverse events, time lag to drug efficacy, and heterogeneity of the disorders being treated. The sequencing of the human genome and high-throughput technologies are enabling pharmacogenetics to have greater influence on treatment approaches. This review highlights key studies and identifies important genes in drug abuse pharmacogenetics that provide a basis for better diagnosis and treatment of drug abuse disorders.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16584126      PMCID: PMC2751437          DOI: 10.1208/aapsj080121

Source DB:  PubMed          Journal:  AAPS J        ISSN: 1550-7416            Impact factor:   4.009


  101 in total

1.  Variable sensitivity to noxious heat is mediated by differential expression of the CGRP gene.

Authors:  Jeffrey S Mogil; Frank Miermeister; Frank Seifert; Kate Strasburg; Katharina Zimmermann; Heiko Reinold; Jean-Sebastien Austin; Nadia Bernardini; Elissa J Chesler; Heiko A Hofmann; Christian Hordo; Karl Messlinger; Kumar V S Nemmani; Andrew L Rankin; Jennifer Ritchie; Angela Siegling; Shad B Smith; Susana Sotocinal; Axel Vater; Sonya G Lehto; Sven Klussmann; Remi Quirion; Martin Michaelis; Marshall Devor; Peter W Reeh
Journal:  Proc Natl Acad Sci U S A       Date:  2005-08-23       Impact factor: 11.205

Review 2.  The genetics of addictions: uncovering the genes.

Authors:  David Goldman; Gabor Oroszi; Francesca Ducci
Journal:  Nat Rev Genet       Date:  2005-07       Impact factor: 53.242

3.  The need for education in pharmacogenomics: a regulatory perspective.

Authors:  F W Frueh; F Goodsaid; A Rudman; S-M Huang; L J Lesko
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

4.  Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G.

Authors:  Ying Zhang; Danxin Wang; Andrew D Johnson; Audrey C Papp; Wolfgang Sadée
Journal:  J Biol Chem       Date:  2005-07-26       Impact factor: 5.157

5.  Melanocortin-1 receptor gene variants affect pain and mu-opioid analgesia in mice and humans.

Authors:  J S Mogil; J Ritchie; S B Smith; K Strasburg; L Kaplan; M R Wallace; R R Romberg; H Bijl; E Y Sarton; R B Fillingim; A Dahan
Journal:  J Med Genet       Date:  2005-07       Impact factor: 6.318

6.  A triple mutation in the second transmembrane domain of mouse dopamine transporter markedly decreases sensitivity to cocaine and methylphenidate.

Authors:  Rong Chen; Dawn D Han; Howard H Gu
Journal:  J Neurochem       Date:  2005-07       Impact factor: 5.372

Review 7.  The role of the cannabinoid system in nicotine addiction.

Authors:  Anna Castañé; Fernando Berrendero; Rafael Maldonado
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

Review 8.  CB1 receptor antagonists for the treatment of nicotine addiction.

Authors:  Caroline Cohen; Ercem Kodas; Guy Griebel
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

9.  Clinical response to morphine in cancer patients and genetic variation in candidate genes.

Authors:  J R Ross; D Rutter; K Welsh; S P Joel; K Goller; A U Wells; R Du Bois; J Riley
Journal:  Pharmacogenomics J       Date:  2005       Impact factor: 3.550

10.  Will nicotine genetics and a nicotine vaccine prevent cigarette smoking and smoking-related diseases?

Authors:  Wayne D Hall
Journal:  PLoS Med       Date:  2005-09-27       Impact factor: 11.069

View more
  17 in total

1.  Interplay of genetic risk factors (CHRNA5-CHRNA3-CHRNB4) and cessation treatments in smoking cessation success.

Authors:  Li-Shiun Chen; Timothy B Baker; Megan E Piper; Naomi Breslau; Dale S Cannon; Kimberly F Doheny; Stephanie M Gogarten; Eric O Johnson; Nancy L Saccone; Jen C Wang; Robert B Weiss; Alison M Goate; Laura Jean Bierut
Journal:  Am J Psychiatry       Date:  2012-07       Impact factor: 18.112

Review 2.  Addiction as a systems failure: focus on adolescence and smoking.

Authors:  Ruben D Baler; Nora D Volkow
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-01-26       Impact factor: 8.829

Review 3.  Genetics and smoking cessation improving outcomes in smokers at risk.

Authors:  Caryn E Lerman; Robert A Schnoll; Marcus R Munafò
Journal:  Am J Prev Med       Date:  2007-12       Impact factor: 5.043

4.  Cost-effectiveness of pharmacogenetic testing to tailor smoking-cessation treatment.

Authors:  D F Heitjan; D A Asch; Riju Ray; Margaret Rukstalis; Freda Patterson; C Lerman
Journal:  Pharmacogenomics J       Date:  2008-03-18       Impact factor: 3.550

Review 5.  Review: Pharmacogenetic aspects of the effect of cytochrome P450 polymorphisms on serotonergic drug metabolism, response, interactions, and adverse effects.

Authors:  J L Pilgrim; D Gerostamoulos; Olaf H Drummer
Journal:  Forensic Sci Med Pathol       Date:  2010-11-04       Impact factor: 2.007

6.  Genetic variation (CHRNA5), medication (combination nicotine replacement therapy vs. varenicline), and smoking cessation.

Authors:  Li-Shiun Chen; Timothy B Baker; Douglas Jorenby; Megan Piper; Nancy Saccone; Eric Johnson; Naomi Breslau; Dorothy Hatsukami; Robert M Carney; Laura J Bierut
Journal:  Drug Alcohol Depend       Date:  2015-06-23       Impact factor: 4.492

Review 7.  Indolealkylamines: biotransformations and potential drug-drug interactions.

Authors:  Ai-Ming Yu
Journal:  AAPS J       Date:  2008-05-03       Impact factor: 4.009

8.  Effects of CYP2D6 status on harmaline metabolism, pharmacokinetics and pharmacodynamics, and a pharmacogenetics-based pharmacokinetic model.

Authors:  Chao Wu; Xi-Ling Jiang; Hong-Wu Shen; Ai-Ming Yu
Journal:  Biochem Pharmacol       Date:  2009-05-13       Impact factor: 5.858

Review 9.  Pathways to precision medicine in smoking cessation treatments.

Authors:  Li-Shiun Chen; Amy Horton; Laura Bierut
Journal:  Neurosci Lett       Date:  2016-05-18       Impact factor: 3.046

Review 10.  Addiction science: Uncovering neurobiological complexity.

Authors:  N D Volkow; R D Baler
Journal:  Neuropharmacology       Date:  2013-05-18       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.